Research programme: hepatitis B virus therapy - Myriad Pharmaceuticals
Alternative Names: MPYS 763Latest Information Update: 20 Feb 2009
At a glance
- Originator Myriad Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 20 Feb 2009 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
- 24 Apr 2006 No development reported - Preclinical for Hepatitis B in USA (unspecified route)
- 13 Jul 2004 Preclinical trials in Hepatitis B in USA (unspecified route)